{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T19:19:36Z","timestamp":1784575176780,"version":"3.55.0"},"reference-count":80,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"vor","delay-in-days":366,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100020595","name":"National Science and Technology Council","doi-asserted-by":"publisher","award":["NSTC 112-2221-E-011-052"],"award-info":[{"award-number":["NSTC 112-2221-E-011-052"]}],"id":[{"id":"10.13039\/100020595","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100020595","name":"National Science and Technology Council","doi-asserted-by":"publisher","award":["NSTC 112-2321-B-016-003"],"award-info":[{"award-number":["NSTC 112-2321-B-016-003"]}],"id":[{"id":"10.13039\/100020595","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007530","name":"National Taiwan University of Science and Technology","doi-asserted-by":"publisher","award":["NTUST-TSGH-112-02"],"award-info":[{"award-number":["NTUST-TSGH-112-02"]}],"id":[{"id":"10.13039\/501100007530","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010425","name":"Tri-Service General Hospital","doi-asserted-by":"publisher","award":["TSGH-A-111010"],"award-info":[{"award-number":["TSGH-A-111010"]}],"id":[{"id":"10.13039\/501100010425","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010425","name":"Tri-Service General Hospital","doi-asserted-by":"publisher","award":["TSGH-A-112008"],"award-info":[{"award-number":["TSGH-A-112008"]}],"id":[{"id":"10.13039\/501100010425","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010425","name":"Tri-Service General Hospital","doi-asserted-by":"publisher","award":["TSGH-D-110036"],"award-info":[{"award-number":["TSGH-D-110036"]}],"id":[{"id":"10.13039\/501100010425","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["li.uscap.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Laboratory Investigation"],"published-print":{"date-parts":[[2023,11]]},"DOI":"10.1016\/j.labinv.2023.100247","type":"journal-article","created":{"date-parts":[[2023,9,21]],"date-time":"2023-09-21T23:53:55Z","timestamp":1695340435000},"page":"100247","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"title":["Deep Learning Can Predict Bevacizumab Therapeutic Effect and Microsatellite Instability Directly from Histology in Epithelial Ovarian Cancer"],"prefix":"10.1016","volume":"103","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9992-6863","authenticated-orcid":false,"given":"Ching-Wei","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-Ching","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi-Jia","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nabila Puspita","family":"Firdi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hikam","family":"Muzakky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tzu-Chien","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Po-Jen","family":"Lai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chih-Hung","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-Chi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mu-Hsien","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chia-Hua","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tai-Kuang","family":"Chao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.labinv.2023.100247_bib1","first-page":"7","article-title":"Cancer statistics, 2019","volume":"69","author":"Siegel","year":"2019","journal-title":"CA Cancer J Clin"},{"issue":"1","key":"10.1016\/j.labinv.2023.100247_bib2","doi-asserted-by":"crossref","first-page":"668","DOI":"10.2174\/1871520620666200908104835","article-title":"Chemoresistance in ovarian cancer: prospects for new drugs","volume":"21","author":"Tendulkar","year":"2021","journal-title":"Anticancer Agents Med Chem"},{"issue":"6","key":"10.1016\/j.labinv.2023.100247_bib3","first-page":"9","article-title":"Epidemiology of ovarian cancer: a review","volume":"14","author":"Reid","year":"2017","journal-title":"Cancer Biol Med"},{"key":"10.1016\/j.labinv.2023.100247_bib4","doi-asserted-by":"crossref","DOI":"10.1016\/j.canep.2021.102045","article-title":"The outcome of patients with serous papillary peritoneal cancer, fallopian tube cancer, and epithelial ovarian cancer by treatment eras: 27 years data from the SEER registry","volume":"75","author":"Pavlidis","year":"2021","journal-title":"Cancer Epidemiol"},{"key":"10.1016\/j.labinv.2023.100247_bib5","first-page":"284","article-title":"Ovarian cancer statistics, 2018","volume":"68","author":"Torre","year":"2018","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.labinv.2023.100247_bib6","article-title":"Epithelial ovarian cancer: review article","volume":"33","author":"Sambasivan","year":"2022","journal-title":"Cancer Treat Res Commun"},{"key":"10.1016\/j.labinv.2023.100247_bib7","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1007\/s10555-014-9538-9","article-title":"Anti-vascular therapies in ovarian cancer: moving beyond anti-VEGF approaches","volume":"34","author":"Choi","year":"2015","journal-title":"Cancer Metastasis Rev"},{"key":"10.1016\/j.labinv.2023.100247_bib8","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1038\/bjc.2015.213","article-title":"Microsatellite instable vs stable colon carcinomas: analysis of tumour heterogeneity, inflammation and angiogenesis","volume":"113","author":"De Smedt","year":"2015","journal-title":"Br J Cancer"},{"key":"10.1016\/j.labinv.2023.100247_bib9","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1097\/GCO.0b013e32834daeed","article-title":"Bevacizumab and ovarian cancer","volume":"24","author":"Sato","year":"2012","journal-title":"Curr Opin Obstet Gynecol"},{"key":"10.1016\/j.labinv.2023.100247_bib10","doi-asserted-by":"crossref","first-page":"2473","DOI":"10.1056\/NEJMoa1104390","article-title":"Incorporation of bevacizumab in the primary treatment of ovarian cancer","volume":"365","author":"Burger","year":"2011","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.labinv.2023.100247_bib11","doi-asserted-by":"crossref","first-page":"2484","DOI":"10.1056\/NEJMoa1103799","article-title":"A\u00a0phase 3 trial of bevacizumab in ovarian cancer","volume":"365","author":"Perren","year":"2011","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.labinv.2023.100247_bib12","first-page":"280","article-title":"Epithelial ovarian cancer: evolution of management in the era of precision medicine","volume":"69","author":"Lhereux","year":"2019","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.labinv.2023.100247_bib13","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1124\/pr.114.010215","article-title":"The great escape; the hallmarks of resistance to antiangiogenic therapy","volume":"67","author":"van Beijnum","year":"2015","journal-title":"Pharmacol Rev"},{"key":"10.1016\/j.labinv.2023.100247_bib14","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/s40661-017-0050-0","article-title":"Bringing new medicines to women with epithelial ovarian cancer: what is the unmet medical need?","volume":"4","author":"Herzog","year":"2017","journal-title":"Gynecol Oncol Res Pract"},{"key":"10.1016\/j.labinv.2023.100247_bib15","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.ygyno.2010.03.018","article-title":"The predictive value of serum VEGF in multiresistant ovarian cancer patients treated with bevacizumab","volume":"118","author":"Smerdel","year":"2010","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.labinv.2023.100247_bib16","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1016\/j.ctrv.2011.11.009","article-title":"Biomarkers in the development of anti-angiogenic therapies for ovarian cancer","volume":"38","author":"Raja","year":"2012","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.labinv.2023.100247_bib17","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/j.ygyno.2014.03.574","article-title":"Explorative investigation of vascular endothelial growth factor receptor expression in primary ovarian cancer and its clinical relevance","volume":"133","author":"Wimberger","year":"2014","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.labinv.2023.100247_bib18","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1016\/j.ygyno.2010.08.016","article-title":"Predictive and prognostic angiogenic markers in a gynecologic oncology group phase II trial of bevacizumab in recurrent and persistent ovarian or peritoneal cancer","volume":"119","author":"Han","year":"2010","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.labinv.2023.100247_bib19","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1016\/j.ygyno.2013.12.003","article-title":"Mismatch repair deficiency in ovarian cancer\u2014molecular characteristics and clinical implications","volume":"132","author":"Xiao","year":"2014","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.labinv.2023.100247_bib20","doi-asserted-by":"crossref","first-page":"9600","DOI":"10.18632\/oncotarget.7144","article-title":"Prevalence and spectrum of BRCA germline variants in mainland Chinese familial breast and ovarian cancer patients","volume":"7","author":"Kim","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.labinv.2023.100247_bib21","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.bulcan.2018.12.008","article-title":"MSI\/MMR-deficient tumor diagnosis: which standard for screening and for diagnosis? Diagnostic modalities for the colon and other sites: differences between tumors","volume":"106","author":"Svrcek","year":"2019","journal-title":"Bull Cancer"},{"key":"10.1016\/j.labinv.2023.100247_bib22","first-page":"1387","article-title":"Incidence of microsatellite instability in synchronous tumors of the ovary and endometrium","volume":"9","author":"Shannon","year":"2003","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.labinv.2023.100247_bib23","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000010253","article-title":"Mapping the human brain during a specific Vojta\u2019s tactile input: the ipsilateral putamen\u2019s role","volume":"97","author":"Sanz-Esteban","year":"2018","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.labinv.2023.100247_bib24","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1148\/rg.313105066","article-title":"Histologic, molecular, and cytogenetic features of ovarian cancers: implications for diagnosis and treatment","volume":"31","author":"Lalwani","year":"2011","journal-title":"Radiographics"},{"key":"10.1016\/j.labinv.2023.100247_bib25","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1158\/2159-8290.CD-14-0863","article-title":"The vigorous immune microenvironment of microsatellite instable colon cancer is balanced by multiple counter-inhibitory checkpoints","volume":"5","author":"Llosa","year":"2015","journal-title":"Cancer Discov"},{"key":"10.1016\/j.labinv.2023.100247_bib26","doi-asserted-by":"crossref","first-page":"2509","DOI":"10.1056\/NEJMoa1500596","article-title":"PD-1 blockade in tumors with mismatch-repair deficiency","volume":"372","author":"Le","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.labinv.2023.100247_bib27","doi-asserted-by":"crossref","first-page":"181","DOI":"10.2147\/CEG.S278054","article-title":"An update on immune checkpoint therapy for the treatment of lynch syndrome","volume":"14","author":"Therkildsen","year":"2021","journal-title":"Clin Exp Gastroenterol"},{"key":"10.1016\/j.labinv.2023.100247_bib28","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2016.1277308","article-title":"Clear cell ovarian cancers with microsatellite instability: a unique subset of ovarian cancers with increased tumor-infiltrating lymphocytes and PD-1\/PD-L1 expression","volume":"6","author":"Howitt","year":"2017","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.labinv.2023.100247_bib29","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1111\/j.1600-065X.2010.00923.x","article-title":"The PD-1 pathway in tolerance and autoimmunity","volume":"236","author":"Francisco","year":"2010","journal-title":"Immunol Rev"},{"key":"10.1016\/j.labinv.2023.100247_bib30","doi-asserted-by":"crossref","first-page":"1865","DOI":"10.1158\/1078-0432.CCR-15-1507","article-title":"The where, the when, and the how of immune monitoring for cancer immunotherapies in the era of checkpoint inhibition","volume":"22","author":"Hegde","year":"2016","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.labinv.2023.100247_bib31","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/j.ccell.2014.10.006","article-title":"Antiangiogenesis strategies revisited: from starving tumors to alleviating hypoxia","volume":"26","author":"Jain","year":"2014","journal-title":"Cancer Cell"},{"key":"10.1016\/j.labinv.2023.100247_bib32","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1038\/nrclinonc.2018.29","article-title":"Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges","volume":"15","author":"Fukumura","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.labinv.2023.100247_bib33","doi-asserted-by":"crossref","first-page":"3733","DOI":"10.3390\/cancers12123733","article-title":"Immunotherapy advances for epithelial ovarian cancer","volume":"12","author":"Hartnett","year":"2020","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.labinv.2023.100247_bib34","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.ygyno.2018.02.009","article-title":"Mismatch repair deficiency is associated with MSI phenotype, increased tumor-infiltrating lymphocytes and PD-L1 expression in immune cells in ovarian cancer","volume":"149","author":"Xiao","year":"2018","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.labinv.2023.100247_bib35","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/00129039-200203000-00001","article-title":"Tissue microarrays: a powerful tool for high-throughput analysis of clinical specimens: a review of the method with validation data","volume":"10","author":"Skacel","year":"2002","journal-title":"Appl Immunohistochem Mol Morphol"},{"key":"10.1016\/j.labinv.2023.100247_bib36","series-title":"StatPearls [Internet]","article-title":"Diagnostic testing accuracy: sensitivity, specificity, predictive values and likelihood ratios","author":"Shreffler","year":"2023"},{"key":"10.1016\/j.labinv.2023.100247_bib37","doi-asserted-by":"crossref","first-page":"W566","DOI":"10.2214\/AJR.12.9888","article-title":"Correctly using sensitivity, specificity, and predictive values in clinical practice: how to avoid three common pitfalls","volume":"200","author":"Naeger","year":"2013","journal-title":"AJR Am J Roentgenol"},{"key":"10.1016\/j.labinv.2023.100247_bib38","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1002\/1097-4679(198811)44:6<1013::AID-JCLP2270440627>3.0.CO;2-Z","article-title":"Understanding the accuracy of tests with cutting scores: the sensitivity, specificity, and predictive value model","volume":"44","author":"Glaros","year":"1988","journal-title":"J\u00a0Clin Psychol"},{"key":"10.1016\/j.labinv.2023.100247_bib39","first-page":"406","article-title":"A\u00a0review of sensitivity, specificity, and likelihood ratios: evaluating the utility of the electrocardiogram as a screening tool in hypertrophic cardiomyopathy","volume":"8","author":"Bolin","year":"2013","journal-title":"Congenit Heart Dis"},{"key":"10.1016\/j.labinv.2023.100247_bib40","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1038\/s41591-018-0177-5","article-title":"Classification and mutation prediction from non\u2013small cell lung cancer histopathology images using deep learning","volume":"24","author":"Coudray","year":"2018","journal-title":"Nat Med"},{"key":"10.1016\/j.labinv.2023.100247_bib41","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1038\/s41591-019-0508-1","article-title":"Clinical-grade computational pathology using weakly supervised deep learning on whole slide images","volume":"25","author":"Campanella","year":"2019","journal-title":"Nat Med"},{"key":"10.1016\/j.labinv.2023.100247_bib42","series-title":"Proceedings of the IEEE Conference on Computer Vision and Pattern Recognition","first-page":"770","article-title":"Deep residual learning for image recognition","author":"He","year":"2016"},{"key":"10.1016\/j.labinv.2023.100247_bib43","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1038\/s42256-020-0200-7","article-title":"High-accuracy prostate cancer pathology using deep learning","volume":"2","author":"Tolkach","year":"2020","journal-title":"Nat Mach Intell"},{"key":"10.1016\/j.labinv.2023.100247_bib44","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.3390\/cancers14071651","article-title":"A\u00a0weakly supervised deep learning method for guiding ovarian cancer treatment and identifying an effective biomarker","volume":"14","author":"Wang","year":"2022","journal-title":"Cancers"},{"key":"10.1016\/j.labinv.2023.100247_bib45","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.artmed.2013.03.001","article-title":"Training artificial neural networks directly on the concordance index for censored data using genetic algorithms","volume":"58","author":"Kalderstam","year":"2013","journal-title":"Artif Intell Med"},{"issue":"1","key":"10.1016\/j.labinv.2023.100247_bib46","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1038\/s42003-023-04588-6","article-title":"Cross-platform normalization enables machine learning model training on microarray and RNA-Seq data simultaneously","volume":"6","author":"Foltz","year":"2023","journal-title":"Commun Biol"},{"key":"10.1016\/j.labinv.2023.100247_bib47","doi-asserted-by":"crossref","DOI":"10.1016\/j.compmedimag.2022.102093","article-title":"Weakly supervised deep learning for prediction of treatment effectiveness on ovarian cancer from histopathology images","volume":"99","author":"Wang","year":"2022","journal-title":"Comput Med Imaging Graph"},{"key":"10.1016\/j.labinv.2023.100247_bib48","doi-asserted-by":"crossref","first-page":"e1162","DOI":"10.1002\/ctm2.1162","article-title":"Ensemble biomarkers for guiding anti-angiogenesis therapy for ovarian cancer using deep learning","volume":"13","author":"Wang","year":"2023","journal-title":"Clin Transl Med"},{"key":"10.1016\/j.labinv.2023.100247_bib49","first-page":"91","article-title":"An introduction to survival statistics: Kaplan-Meier analysis","volume":"7","author":"Dudley","year":"2016","journal-title":"J\u00a0Adv Pract Oncol"},{"key":"10.1016\/j.labinv.2023.100247_bib50","doi-asserted-by":"crossref","DOI":"10.1016\/j.compmedimag.2023.102233","article-title":"Interpretable attention-based deep learning ensemble for personalized ovarian cancer treatment without manual annotations","volume":"107","author":"Wang","year":"2023","journal-title":"Comput Med Imaging Graph"},{"key":"10.1016\/j.labinv.2023.100247_bib51","series-title":"SPSS for Windows, Rel. 15.0","year":"2006"},{"key":"10.1016\/j.labinv.2023.100247_bib52","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.ygyno.2008.01.012","article-title":"A\u00a0candidate precursor to pelvic serous cancer (p53 signature) and its prevalence in ovaries and fallopian tubes from women with BRCA mutations","volume":"109","author":"Folkins","year":"2008","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.labinv.2023.100247_bib53","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.ygeno.2014.08.016","article-title":"Microsatellite instability, promoter methylation and protein expression of the DNA mismatch repair genes in epithelial ovarian cancer","volume":"104","author":"S","year":"2014","journal-title":"Genomics"},{"key":"10.1016\/j.labinv.2023.100247_bib54","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1007\/s10456-017-9552-y","article-title":"Anti-angiogenesis for cancer revisited: is there a role for combinations with immunotherapy?","volume":"20","author":"Ramjiawan","year":"2017","journal-title":"Angiogenesis"},{"issue":"suppl 1","key":"10.1016\/j.labinv.2023.100247_bib55","doi-asserted-by":"crossref","first-page":"i33","DOI":"10.1093\/annonc\/mdw093","article-title":"Anti-angiogenic agents in ovarian cancer: past, present, and future","volume":"27","author":"Monk","year":"2016","journal-title":"Ann Oncol"},{"key":"10.1016\/j.labinv.2023.100247_bib56","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1055\/a-1128-0280","article-title":"Treatment of recurrent epithelial ovarian cancer","volume":"80","author":"Claussen","year":"2020","journal-title":"Geburtshilfe Frauenheilkd"},{"key":"10.1016\/j.labinv.2023.100247_bib57","doi-asserted-by":"crossref","first-page":"225","DOI":"10.2217\/fon-2019-0042","article-title":"Bevacizumab use in the frontline, maintenance and recurrent settings for ovarian cancer","volume":"16","author":"Haunschild","year":"2020","journal-title":"Future Oncol"},{"key":"10.1016\/j.labinv.2023.100247_bib58","doi-asserted-by":"crossref","first-page":"3684","DOI":"10.1158\/1078-0432.CCR-16-1859","article-title":"CT perfusion as an early biomarker of treatment efficacy in advanced ovarian cancer: an ACRIN and GOG Study","volume":"23","author":"Ng","year":"2017","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.labinv.2023.100247_bib59","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1038\/nrd1381","article-title":"Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer","volume":"3","author":"Ferrara","year":"2004","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.labinv.2023.100247_bib60","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2020.102017","article-title":"Bevacizumab (Avastin\u00ae) in cancer treatment: a review of 15 years of clinical experience and future outlook","volume":"86","author":"Garcia","year":"2020","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.labinv.2023.100247_bib61","doi-asserted-by":"crossref","first-page":"2943","DOI":"10.1158\/0008-5472.CAN-12-4354","article-title":"Vascular normalization as an emerging strategy to enhance cancer immunotherapy","volume":"73","author":"Huang","year":"2013","journal-title":"Cancer Res"},{"key":"10.1016\/j.labinv.2023.100247_bib62","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1158\/2159-8290.CD-13-0985","article-title":"T-cell and NK-cell infiltration into solid tumors: a key limiting factor for efficacious cancer immunotherapy","volume":"4","author":"Melero","year":"2014","journal-title":"Cancer Discov"},{"key":"10.1016\/j.labinv.2023.100247_bib63","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1186\/s12943-019-0974-6","article-title":"Synergistic effect of immune checkpoint blockade and anti-angiogenesis in cancer treatment","volume":"18","author":"Yi","year":"2019","journal-title":"Mol Cancer"},{"key":"10.1016\/j.labinv.2023.100247_bib64","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1158\/1078-0432.CCR-16-0387","article-title":"Expression of vascular endothelial growth factor in ovarian cancer inhibits tumor immunity through the accumulation of myeloid-derived suppressor cells","volume":"23","author":"Horikawa","year":"2017","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.labinv.2023.100247_bib65","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.jim.2004.01.011","article-title":"Isolation of human antibodies to tumor-associated endothelial cell markers by in\u00a0vitro human endothelial cell selection with phage display libraries","volume":"287","author":"Mutuberria","year":"2004","journal-title":"J\u00a0Immunol Methods"},{"key":"10.1016\/j.labinv.2023.100247_bib66","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1080\/02688697.2019.1690127","article-title":"Cerebellar glioblastoma in an NF1 patient. Is it surgical debulking really necessary?","volume":"34","author":"Flower","year":"2020","journal-title":"Br J Neurosurg"},{"key":"10.1016\/j.labinv.2023.100247_bib67","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1007\/s10689-018-00117-1","article-title":"Recent advances in Lynch syndrome","volume":"18","author":"Biller","year":"2019","journal-title":"Fam Cancer"},{"key":"10.1016\/j.labinv.2023.100247_bib68","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1148\/rg.2018170075","article-title":"Lynch syndrome: genomics update and imaging review","volume":"38","author":"Cox","year":"2018","journal-title":"Radiographics"},{"key":"10.1016\/j.labinv.2023.100247_bib69","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-021-91974-x","article-title":"Comparison of microsatellite instability detection by immunohistochemistry and molecular techniques in colorectal and endometrial cancer","volume":"11","author":"Dedeurwaerdere","year":"2021","journal-title":"Sci Rep"},{"key":"10.1016\/j.labinv.2023.100247_bib70","doi-asserted-by":"crossref","first-page":"4015","DOI":"10.1200\/JCO.2015.62.3397","article-title":"Safety and antitumor activity of anti-PD-1 antibody, nivolumab, in patients with platinum-resistant ovarian cancer","volume":"33","author":"Hamanishi","year":"2015","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.labinv.2023.100247_bib71","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1111\/jcpt.13364","article-title":"Dramatic response to single-agent atezolizumab in a patient with MSI-H serous ovarian cancer","volume":"46","author":"Ak","year":"2021","journal-title":"J\u00a0Clin Pharm Ther"},{"key":"10.1016\/j.labinv.2023.100247_bib72","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1093\/annonc\/mdz135","article-title":"Antitumor activity and safety of pembrolizumab in patients with advanced recurrent ovarian cancer: results from the phase II KEYNOTE-100 study","volume":"30","author":"Matulonis","year":"2019","journal-title":"Ann Oncol"},{"key":"10.1016\/j.labinv.2023.100247_bib73","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/j.soc.2019.02.002","article-title":"Immunotherapy in ovarian cancer","volume":"28","author":"Wang","year":"2019","journal-title":"Surg Oncol Clin N Am"},{"key":"10.1016\/j.labinv.2023.100247_bib74","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1186\/s12885-021-07942-1","article-title":"A\u00a0next-generation sequencing-based strategy combining microsatellite instability and tumor mutation burden for comprehensive molecular diagnosis of advanced colorectal cancer","volume":"21","author":"Xiao","year":"2021","journal-title":"BMC Cancer"},{"key":"10.1016\/j.labinv.2023.100247_bib75","doi-asserted-by":"crossref","first-page":"2638","DOI":"10.1007\/s12325-019-01051-z","article-title":"Existing and emerging biomarkers for immune checkpoint immunotherapy in solid tumors","volume":"36","author":"Arora","year":"2019","journal-title":"Adv Ther"},{"key":"10.1016\/j.labinv.2023.100247_bib76","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/j.ygyno.2021.11.008","article-title":"Corrigendum to \u201cLynch syndrome-associated epithelial ovarian cancer and its immunological profile\u201d [Gynecologic Oncology 162 (2021) 686-693]","volume":"164","author":"Rasmussen","year":"2022","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.labinv.2023.100247_bib77","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/JCO.19.02105","article-title":"Efficacy of pembrolizumab in patients with noncolorectal high microsatellite instability\/mismatch repair-deficient cancer: results from the phase II KEYNOTE-158 study","volume":"38","author":"Marabelle","year":"2020","journal-title":"J\u00a0Clin Oncol"},{"issue":"3","key":"10.1016\/j.labinv.2023.100247_bib78","first-page":"13","article-title":"Challenges in implementing an advance care planning programme in long-term care","volume":"29","author":"Thompson","year":"2017","journal-title":"Nursing Older People"},{"key":"10.1016\/j.labinv.2023.100247_bib79","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1186\/s13073-021-00968-x","article-title":"Deep learning in cancer diagnosis, prognosis and treatment selection","volume":"13","author":"Tran","year":"2021","journal-title":"Genome Med"},{"key":"10.1016\/j.labinv.2023.100247_bib80","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1038\/s43018-020-0087-6","article-title":"Pan-cancer image-based detection of clinically actionable genetic alterations","volume":"1","author":"Kather","year":"2020","journal-title":"Nat Cancer"}],"container-title":["Laboratory Investigation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0023683723001903?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0023683723001903?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,20]],"date-time":"2025-09-20T19:59:12Z","timestamp":1758398352000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0023683723001903"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11]]},"references-count":80,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2023,11]]}},"alternative-id":["S0023683723001903"],"URL":"https:\/\/doi.org\/10.1016\/j.labinv.2023.100247","relation":{},"ISSN":["0023-6837"],"issn-type":[{"value":"0023-6837","type":"print"}],"subject":[],"published":{"date-parts":[[2023,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Deep Learning Can Predict Bevacizumab Therapeutic Effect and Microsatellite Instability Directly from Histology in Epithelial Ovarian Cancer","name":"articletitle","label":"Article Title"},{"value":"Laboratory Investigation","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.labinv.2023.100247","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 United States & Canadian Academy of Pathology. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"100247"}}